Insider Selling: Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Insider Sells 1,000 Shares of Stock

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) insider Sang Yi sold 1,000 shares of the company's stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total value of $95,000.00. Following the transaction, the insider now directly owns 20,424 shares in the company, valued at approximately $1,940,280. The trade was a 4.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Zimmer Biomet Stock Performance

NYSE ZBH traded down $2.03 on Friday, hitting $91.23. 1,370,283 shares of the company's stock traded hands, compared to its average volume of 1,789,177. The firm has a market capitalization of $18.05 billion, a PE ratio of 20.50, a P/E/G ratio of 1.95 and a beta of 0.72. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $116.71. The firm's 50-day moving average price is $96.71 and its two-hundred day moving average price is $103.70. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The firm's quarterly revenue was up 1.1% on a year-over-year basis. During the same period in the previous year, the firm posted $1.94 earnings per share. As a group, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 26th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.05%. Zimmer Biomet's payout ratio is 21.24%.

Institutional Trading of Zimmer Biomet

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Ameriprise Financial Inc. increased its holdings in shares of Zimmer Biomet by 236.0% during the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider's stock valued at $517,039,000 after purchasing an additional 3,208,596 shares in the last quarter. Franklin Resources Inc. grew its position in Zimmer Biomet by 398.7% during the fourth quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock valued at $369,469,000 after buying an additional 2,796,372 shares during the period. Norges Bank purchased a new position in Zimmer Biomet in the fourth quarter valued at $216,223,000. Dodge & Cox increased its holdings in Zimmer Biomet by 12.0% in the fourth quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider's stock valued at $2,019,480,000 after buying an additional 2,044,645 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of Zimmer Biomet by 251.3% during the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider's stock worth $235,571,000 after acquiring an additional 1,488,918 shares in the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently weighed in on ZBH shares. Truist Financial set a $101.00 target price on Zimmer Biomet in a research note on Tuesday, May 6th. JPMorgan Chase & Co. dropped their price target on Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. JMP Securities cut their price objective on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a report on Wednesday, May 7th. Morgan Stanley decreased their price objective on shares of Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Finally, BTIG Research reissued a "buy" rating on shares of Zimmer Biomet in a research report on Monday, April 14th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $111.53.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.